The disruption of Keap1-Nrf2 interaction by ferroptosis-inducing compounds leads to the accumulation of Nrf2, ultimately reducing cancer cell susceptibility to ferroptosis (Sun et al., 2016). The gene discussed is NFE2L2; the disease is cancer.